Raj Tummala

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 9

Top Topics

Disease Activity

Systemic Lupus Erythematosus

Top Venues

Clinical pharmacokinetics

Rheumatology (Oxford, England)

Annals of the rheumatic diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Weifeng Tang, Raj Tummala, Joachim Almquist, Michael Hwang, Wendy I White, David W Boulton, Alexander MacDonald
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Clinical pharmacokinetics 62 (5) (2023)
Weifeng Tang, Raj Tummala, Joachim Almquist, Michael Hwang, Wendy I White, David W Boulton, Alexander MacDonald
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Clinical pharmacokinetics 62 (5) (2023)
Eric F Morand, Gabriel Abreu, Richard A Furie, Vera Golder, Raj Tummala
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Annals of the rheumatic diseases (2023)
Weifeng Tang, Raj Tummala, Joachim Almquist, Michael Hwang, Wendy I White, David W Boulton, Alexander MacDonald
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Clinical pharmacokinetics (2023)
Weifeng Tang, Raj Tummala, Joachim Almquist, Michael Hwang, Wendy I White, David W Boulton, Alexander MacDonald
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Clinical pharmacokinetics 62 (5) (2023)
Donald Stull, Sean O'Quinn, Betsy Williams, Stephanie Bean, Erik Schwetje, Gabriel Abreu, Raj Tummala
Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials. Rheumatology (Oxford, England) 61 (12) (2022)
Ian N Bruce, Ronald F van Vollenhoven, Eric F Morand, Richard A Furie, Susan Manzi, William B White, Gabriel Abreu, Raj Tummala
Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post-hoc analysis of the TULIP-1 and TULIP-2 trials. Rheumatology (Oxford, England) (2022)
Richard Furie, Eric F Morand, Anca D Askanase, Edward M Vital, Joan T Merrill, Rubana N Kalyani, Gabriel Abreu, Lilia Pineda, Raj Tummala
Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus 30 (8) (2021)
Yen Lin Chia, Jianchun Zhang, Raj Tummala, Tomas Rouse, Richard A Furie, Eric F Morand
Relationship of Anifrolumab Pharmacokinetics With Efficacy and Safety in Patients With Systemic Lupus Erythematosus. Rheumatology (Oxford, England) (2021)